News

The label update is based on results from the ENSURE-AF study, the largest, prospective randomised clinical trial of an anticoagulant for cardioversion in patients with NVAF. The study

Limited partners of the Fund include industry veterans in other geographic markets, such as China Regenerative Medicine International Limited. "The sale of Obagi marks additional progress in our

Evenity is an investigational bone-forming monoclonal antibody developed for the treatment of osteoporosis. The treatment is not yet approved by any regulatory authority. The decision has been taken

Ciclesonides are included in the corticosteroids class of medications, and are approved to treat asthma (Alvesco) and allergic rhinitis (Omnaris and Zetonna). “We are excited to announce this

It comes after an open research competition led by the National Institute for Health Research (NIHR). Following the success of this initial competition, a call for a second

The company, dubbed Qrativ, will leverage on the medical expertise and clinical data of Mayo Clinic’s and on the AI-driven knowledge synthesis platform of nference. Initially, Qrativ will focus

Under the deal, Sanofi will secure $97.5m upfront payment, as well as up to $27.5m based on the achievement of certain regulatory and manufacturing-related milestones. Once the deal

Biognosys' contract research services and tools are successfully applied in biomarker research, drug and target discovery, pathway modeling, mechanisms of action studies and many other areas. Its market

ALV-107 utilises the proprietary Alivio inflammation-targeting technology. The data were presented at the 2017 Drug Discovery and Therapy World Congress in Boston, Massachusetts. "One of the greatest needs